当前位置：首页 > 文献互助 > 互助详情

期刊论文Antibody Data Analysis from Diverse Immune Libraries复制

用户RdN6vXU76fqU 3个月前 161 已关闭

DOI: 10.1101/pdb.prot108627复制

文献链接: http://www.cshprotocols.org/lookup/doi/10.1101/pdb.prot108627复制

其他信息:

出版社: Cold Spring Harbor Laboratory
作者: Ahmed S. Fahad; Matías F. Gutiérrez-Gonzalez; Bharat Madan; Brandon J. DeKosky

上一篇：Genetic landscape of atopic dermatitis

下一篇：Discovery of novel peptide–dehydroepiandrosterone hybrids inducing endoplasmic reticulum stress with effective in vitro and in vivo anti-melanoma activities

互助时间线

2025-03-03 15:10:06 [仲裁结果]

审核员确认了没有正确的应助文件, 关闭了该帖子, 系统自动退返积分

2025-03-03 14:32:08 [转为仲裁]

已驳回3次, 求助状态自动转为仲裁中, 请耐心等待人工审核, 预计耗时1-3个工作日

2025-03-03 14:32:08 [驳回应助]

楼主驳回了追星族应助的文件, 求助状态回到求助中

备注: 同上述理由

2025-03-03 14:31:49 [上传文件]

追星族上传了文件(pdf 580.00 KB), 求助状态变成待确认

2025-03-03 14:31:43 [驳回应助]

楼主驳回了用户4dqcMiQ9st2k应助的文件, 求助状态回到求助中

备注: 同上述理由

2025-03-03 14:31:11 [上传文件]

用户4dqcMiQ9st2k上传了文件(pdf 580.00 KB), 求助状态变成待确认

2025-03-03 14:31:03 [驳回应助]

楼主驳回了用户DgcHfqk6v38y应助的文件, 求助状态回到求助中

备注: 上传的文献doi是:10.1101/pdb.top107772，与求助的文章不符

2025-03-03 14:23:10 [上传文件]

用户DgcHfqk6v38y上传了文件(pdf 580.00 KB), 求助状态变成待确认

2025-03-03 12:30:46 [发起求助]

最新发布的求助

Discovery of a Selective, Novel TGF-βR1 Inhibitor GFH018 for the Treatment of Solid Tumors 7小时前

Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments 13小时前

Engineering yeast for high-level production of β-farnesene from sole methanol 13小时前

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia 13小时前

A hybrid machine learning framework leveraging biophysicochemical insights for scalable discovery of protein-ligand interactions 14小时前

Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions 14小时前

… of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial … 15小时前

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). 15小时前

… of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial … 16小时前

Animal models of vasculitis 17小时前

Probing the world of cytochrome P450 enzymes 18小时前

Parasomnia induced by lemborexant: a case report 18小时前